Effectiveness of 3,3′-Diindolylmethane Supplements on Favoring the Benign Estrogen Metabolism Pathway and Decreasing Body Fat in Premenopausal Women

References

• Instituto Nacional de Estadística y Geografía (INEGI). Características de las defunciones registradas en México durante 2017. México: INEGI; 2018 [Accessed September 2021]. chromeextension://efaidnbmnnnibpcajpcglclefindmkaj/viewer.html?pdfurl=https%3A%2F%2Fwww.inegi.org.mx%2Fcontenidos%2Fsaladeprensa%2Fboletines%2F2018%2FEstSociodemo%2FDEFUNCIONES2017.pdf&clen=2698834&chunk=true.
   Google Scholar
• Institute of Medicine (IOM). Breast cancer and the environment: A life course approach. Washington (DC): The National Academies Press; 2012 [Accessed September 2021]. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/viewer.html?pdfurl=https%3A%2F%2Fwww.komen.org%2Fwp-content%2Fuploads%2FIOM20Report-Breast20Cancer20and20the20Environment-A20Life20Course20Approach.pdf&clen=3046243&chunk=true.
   Google Scholar
• Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schünemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, et al. Estrogen metabolism and risk of breast cancer a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000;11(6):635–640. doi:10.1097/00001648-200011000-00004.
   PubMed Web of Science ®Google Scholar
• Fowke JH, Qi D, Bradlow HL, Shu XO, Gao YT, Cheng JR, Jin F, Zheng W. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection. Steroids. 2003;68(1):65–72. doi: 10.1016/s0039-128x(02)00116-2.
   PubMed Web of Science ®Google Scholar
• Kabat GC, O’Leary ES, Gammon MD, Sepkovic DW, Teitelbaum SL, Britton JA, Terry MB, Neugut AI, Bradlow HL. Estrogen metabolism and breast cancer. Epidemiology. 2006;17(1):80–88. doi: 10.1097/01.ede.0000190543.40801.75.
   PubMed Web of Science ®Google Scholar
• Im A, Vogel VG, Ahrendt G, Lloyd S, Ragin C, Garte S, Taioli E. Urinary estrogen metabolites in women at risk for breast cancer. Carcinogenesis. 2009;30(9):1532–1535. doi: 10.1093/carcin/bgp139.
   PubMed Web of Science ®Google Scholar
• Ho GH, Luo XW, Ji CY, Foo SC, Ng EH. Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann AcadMed Singapore. 1998;27(2):294–299.
   PubMedGoogle Scholar
• Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001;344(4):276–285. doi: 10.1056/NEJM200101253440407.
   PubMed Web of Science ®Google Scholar
• Dallal CM, Stone RA, Cauley JA, Ness RB, Vogel VG, Fentiman IS, Fowke JH, Krogh V, Loft S, Meilahn EN, et al. Urinary estrogen metabolites and breast cancer: a combined analysis of individual level data. Int J Biol Markers. 2013;28(1):3–16. doi: 10.5301/JBM.2012.9353.
   PubMed Web of Science ®Google Scholar
• Muti P, Westerlind K, Wu T, Grimaldi T, De Berry J, Schünemann H, Freudenheim JL, Hill H, Carruba G, Bradlow L. Urinary estrogen metabolites and prostate cancer: a case-control study in the United States. Cancer Causes Control. 2002;13(10):947–955. doi:10.1023/A:1021986811425
   PubMed Web of Science ®Google Scholar
• Chan EK, Sepkovic DW, Yoo Bowne HJ, Yu GP, Schantz SP. A hormonal association between estrogen metabolism and proliferative thyroid disease. Otolaryngol Head Neck Surg. 2006;134(6):893–900. doi:10.1016/j.otohns.2006.01.020
   PubMed Web of Science ®Google Scholar
• Campisi I, Granata OM, Cocciadiferro L, Calabrò M, Polito LM, Carruba G. 16alpha-hydroxyestrone inhibits estrogen sulfotransferase activity in human liver cancer cells. Ann N Y Acad Sci. 2009;1155:237–241. doi: 10.1111/j.1749-6632.2008.03694.x.
   PubMed Web of Science ®Google Scholar
• Khan WA, Alsamghan AS, Khan MWA. Endometrial cancer patients have high affinity antibodies for estrogen metabolite-receptor aggregate: a potential biomarker for EC. J Obstet Gynaecol Res. 2020;46(10):2115–2125. doi:10.1111/jog.14413.
   PubMed Web of Science ®Google Scholar
• Sawicka E, Saczko J, Roik J, Kulbacka J, Piwowar A. Effect of interaction between 17β-estradiol, 2-methoxyestradiol and 16α-hydroxyestrone with chromium (VI) on ovary cancer line SKOV-3: Preliminary study. Molecules. 2020;25(21):5214. doi:10.3390/molecules25215214
   PubMed Web of Science ®Google Scholar
• Sowers MR, Crawford S, McConnell DS, Randolph JF, JrGold EB, Wilkin MK, Lasley B. Selected diet and lifestyle factors are associated with estrogen metabolites in a multiracial/ethnic population of women. J Nutr. 2006;136(6):1588–1595. doi:10.1093/jn/136.6.1588
   PubMed Web of Science ®Google Scholar
• Godínez-Martínez EY, Santillán R, Lemus AE, Sámano R, Tolentino M, Rodríguez AL, Juárez AR. Determination of 2-hydroxyestrone/16α-hydroxyestrone ratio in urine of Mexican women as a risk indicator for breast cancer and its relationship with other risk factors. Nutr Hosp. 2014;31(2):835–840. doi: 10.3305/nh.2015.31.2.8172.
   PubMed Web of Science ®Google Scholar
• Thomson CA, Ho E, Strom MB. Chemopreventive properties of 3,3′-diindolylmethane in breast cancer: evidence from experimental and human studies. Nutr Rev. 2016;74(7):432–443. doi: 10.1093/nutrit/nuw010.
   PubMed Web of Science ®Google Scholar
• Wong GY, Bradlow L, Sepkovic D, Mehl S, Mailman J, Osborne MP. Dose-ranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem Suppl. 1997;28–29:111–116. doi:10.1002/(sici)1097-4644(1997)28/29+ <111::aid-jcb12 > 3.0.co;2-k
   PubMedGoogle Scholar
• Reed GA, Peterson KS, Smith HJ, Gray JC, Sullivan DK, Mayo MS, Crowell JA, Hurwitz A. A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1953–1960. doi: 10.1158/1055-9965.EPI-05-0121.
   PubMed Web of Science ®Google Scholar
• Oganesian A, Hendricks JD, Pereira CB, Orner GA, Bailey GS, Williams DE. Potency of dietary indole-3-carbinol as a promoter of aflatoxin B1-initiated hepatocarcinogenesis: results from a 9000 animal tumor study. Carcinogenesis. 1999;20(3):453–458. doi: 10.1093/carcin/20.3.453.
   PubMed Web of Science ®Google Scholar
• De Kruif CA, Marsman JW, Venekamp JC, Falke HE, Noordhoek J, Blaauboer BJ, Wortelboer HM. Structure elucidation of acid reaction products of indole-3-carbinol: detection in vivo and enzyme induction in vitro. Chem Biol Interct. 1991;80(3):303–315. doi:10.1016/0009-2797(91)90090-T
   PubMed Web of Science ®Google Scholar
• Anderton MJ, Manson MM, Verschoyle R, Gescher A, Steward WP, Williams ML, Mager DE. Physiological modeling of formulated and crystalline 3,3′-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos. 2004;32(6):632–638. doi:10.1124/dmd.32.6.632
   PubMed Web of Science ®Google Scholar
• Estramet 2/16 Kit. EstrametTM Immunoassay Kit for Urinary Estrogen Metabolites. Blue Bell (PA): Immuna Care Corporation; 2007 [Accessed September 2021]. http://www.immunacare.com/results.htm.
   Google Scholar
• Reed GA, Sunega JM, Sullivan DK, Gray JC, Mayo MS, Crowell JA, Hurwitz A. Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3′-diindolylmethane in healthy subjects. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2619–2624. doi: 10.1158/1055-9965.EPI-08-0520.
   PubMed Web of Science ®Google Scholar
• BioResponse Nutrients. Cleveland (OH). BioResponse, LLC; 2008-2021 [Accessed September 2021]. https://www.bioresponse.com/product/bd1-bioresponse-dim-150-2/.
   Google Scholar
• Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF. Pilot study: effect of 3,3′-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer. 2004;50(2):161–167. doi: 10.1207/s15327914nc5002_5.
   PubMed Web of Science ®Google Scholar
• Kushi LH, Byers T, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, Gapstur S, Patel AV, Andrews K, et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012;62(1):30–67. doi: 10.3322/caac.20140.
   PubMed Web of Science ®Google Scholar
• Lohman TG, Roche AF, Martorell R. Chapter 1. Stature, recumbent, and weight; p. 3,4; Chapter 4. Circunferences; p. 39. Anthropometric standardization reference manual. Champaign (IL): Human Kinetics Books; 1998.
   Google Scholar
• Dawson B, Trapp R. Chapter 7, Preguntas de Investigación sobre la media en tres o más grupos. In: Biostadística Médica. México (Ciudad de México): Editorial Manual Moderno; 2002. pp. 170.
   Google Scholar
• Nikitina D, Llacuachaqui M, Sepkovic D, Bradlow HL, Narod SA, Kotsopoulos J. The effect of oral 3,3´-diindolylmethane supplementation on the 2:16α-OHE ratio in BRCA1 mutation carriers. Fam Cancer. 2015;14(2):281–286. doi: 10.1007/s10689-015-9783-2.
   PubMed Web of Science ®Google Scholar
• Reed GA, Arneson DW, Putnam WC, Smith HJ, Gray JC, Sullivan DK, Mayo MS, Crowell JA, Hurwitz A. Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3´-diindolylmethane. Cancer Epidemiol Biomarkers Prev. 2006;15(12):2477–2481. doi: 10.1158/1055-9965.EPI-06-0396.
   PubMed Web of Science ®Google Scholar
• Salazar-Flores J, Torres-Reyes LA, Martínez-Cortés G, Rubi-Castellanos R, Sosa-Macías M, Muñoz-Valle JF, González-González C, Ramírez A, Román R, Méndez JL, et al. Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico. Genet Test Mol Biomarkers. 2012;16(9):1098–1104. doi: 10.1089/gtmb.2012.0055.
   PubMed Web of Science ®Google Scholar
• Naranjo M-EG, Rodrigues-Soares F, Peñas-Lledó EM, Tarazona-Santos E, Fariñas H, Rodeiro I, Terán E, Grazina M, Moya GE, López-López M, et al. Interethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and predicted drug metabolism phenotypes among 6060 Ibero- and Native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics. OMICS. 2018;22(9):575–588. doi: 10.1089/omi.2018.0114.
   PubMed Web of Science ®Google Scholar
• Thomson CA, Chow HHS, Wertheim BC, Roe DJ, Stopeck A, Maskarinec G, Altbach M, Chalasani P, Huang C, Strom MB, et al. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Res Treat. 2017;165(1):97–107. doi:10.1007/s10549-017-4292-7
   PubMed Web of Science ®Google Scholar
• Paltsev M, Kiselev V, Muyzhnek E, Drukh V, Igor K, Pchelintseva O. Comparative preclinical pharmacokinetics study of 3,3′-diindolylmethane formulations: is personalized treatment and targeted chemoprevention in the horizon? EPMA J. 2013;4(1):25. doi: 10.1186/1878-5085-4-25.
   PubMedGoogle Scholar
• Paracchini V, Pedotti P, Raimondi S, Garte S, Bradlow HL, Sepkovic DW, Taioli E. A common CYP1B polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702–706. doi: 10.1515/CCLM.2005.119.
   PubMed Web of Science ®Google Scholar
• Taioli E, Bradlow HL, Garbers SV, Sepkovic DW, Osborne MP, Trachman J, Ganguly S, Garte SJ. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect Prev. 1999;23(3):232–237. doi: 10.1515/CCLM.2005.119.
   PubMedGoogle Scholar
• Michnovicz JJ, Bradlow HL. Induction of estradiol metabolism by dietary indole-3-carbinol in humans. J Natl Cancer Inst. 1990;82(11):947–949. doi: 10.1093/jnci/82.11.947.
   PubMedGoogle Scholar
• Bradlow HL, Michnovicz JJ, Halper M, Miller DG, Wong GY, Osborne MP. Long-term responses of women to indole-3-carbinol or a high fiber diet. Cancer Epidemiol Biomarkers Prev. 1994;3(7):591–595.
   PubMed Web of Science ®Google Scholar
• Michnovicz JJ, Adlercreutz H, Bradlow HL. Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J Natl Cancer Inst. 1997;89(10):718–723. doi: 10.1093/jnci/89.10.718.
   PubMedGoogle Scholar
• Michnovicz JJ. Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol. Int J Obes Relat Metab Disord. 1998;22(3):227–229. doi: 10.1038/sj.ijo.0800573.
   PubMed Web of Science ®Google Scholar
• Dallal C, Taioli E. Urinary 2/16 estrogen metabolite ratio levels in healthy women: a review of the literature. Mutat Res. 2010;705(2):154–162. doi:10.1016/j.mrrev.2010.06.004
   PubMed Web of Science ®Google Scholar
• Napoli N, Vattikuti S, Yarramaneni J, Giri TK, Nekkalapu S, Qualls C, Armamento-Villareal RC. Increased 2-hydroxylation of estrogen is associated with lower body fat and increased lean body mass in postmenopausal women. Maturitas. 2012;72(1):66–71. doi: 10.1016/j.maturitas.2012.02.002.
   PubMed Web of Science ®Google Scholar
• Yang H, Seo SG, Shin SH, Min S, Kang MJ, Yoo R, Kwon JY, Yue S, Kim KH, Cheng J-X, et al. 3,3′-Diindolylmethane suppresses high-fat diet-induced obesity through inhibiting adipogenesis of pre-adipocytes by targeting USP2 activity. Mol Nutr Food Res. 2017;61(10):1700119. doi:10.1002/mnfr.201700119
   Web of Science ®Google Scholar